Should Enrichment With Natriuretic Peptide Levels Be Mandatory in Global Clinical Trials?

Adriaan A. Voors

doi:10.1016/j.jchf.2020.01.007

Should Enrichment With Natriuretic Peptide Levels Be Mandatory in Global Clinical Trials?

Adriaan A. Voors^*

^*Corresponding author for this work

Cardiovascular Centre (CVC)

Research output: Contribution to journal › Editorial › Academic › peer-review

3 Citations (Scopus)

58 Downloads (Pure)

Original language	English
Pages (from-to)	369-371
Number of pages	3
Journal	JACC. Heart failure
Volume	8
Issue number	5
DOIs	https://doi.org/10.1016/j.jchf.2020.01.007
Publication status	Published - May-2020

Keywords

cardiac biomarkers
clinical trials
heart failure with reduced ejection fraction
HEART-FAILURE

Access to Document

10.1016/j.jchf.2020.01.007

Should Enrichment With Natriuretic Peptide Levels Be Mandatory in Global Clinical Trials?Final publisher's version, 99.8 KBLicence: Taverne

Handle.net

Persistent link

Cite this

@article{8b716d4ad5504afda18a641a781ee726,

title = "Should Enrichment With Natriuretic Peptide Levels Be Mandatory in Global Clinical Trials?",

keywords = "cardiac biomarkers, clinical trials, heart failure with reduced ejection fraction, HEART-FAILURE",

author = "Voors, \{Adriaan A.\}",

year = "2020",

month = may,

doi = "10.1016/j.jchf.2020.01.007",

language = "English",

volume = "8",

pages = "369--371",

journal = "JACC. Heart failure",

issn = "2213-1779",